title: Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD.
abstract: BACKGROUND
  Flow response after administration of a bronchodilator is widely used as an indicator of reversibility of airflow limitation in chronic obstructive pulmonary disease (COPD). We hypothesized that the association between flow and volume responses would reverse along with the progression of the disease.
  
  
  METHODS
  We used the database of a large primary care diagnostic centre containing pre- and postbronchodilator tests of patients referred for spirometry by their GP. Patients 40 years with a smoking history were categorized into Global initiative for chronic obstructive lung disease (GOLD) stages I-IV. Flow and volume responses (DeltaFVC and DeltaFEV(1), respectively) were calculated and compared between the GOLD stages using linear regression analysis.
  
  
  RESULTS
  About 2210 patients (63% males, 49% current smokers) were analysed. Four hundred and forty-two patients were classified into GOLD stage I, 1297 in GOLD II, 426 in GOLD III, and 45 in GOLD IV. The overall mean values for DeltaFEV(1) and DeltaFVC were 0.180 (sd 0.150) and 0.226l (sd 0.227). DeltaFEV(1) decreased as the GOLD stage was more severe, whereas DeltaFVC increased (P<0.001). There was a clear positive correlation between DeltaFEV(1) and DeltaFVC within each GOLD stage (P<0.01), but when FVC response was plotted against FEV(1) response the slope of the regression line became gradually steeper with each more severe GOLD stage (P<0.001).
  
  
  CONCLUSIONS
  Our hypothesis that COPD patients on the mild side of the severity spectrum differ from patients on the severe side regarding the association between their bronchodilator flow and volume responses was confirmed. The difference is probably explained by the higher degree of loss of lung elastic recoil and/or compression of the smaller airways due to enlarged air spaces that accompanies the progression of COPD to the more severe stages.
authors.affiliation: Department of General Practice, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands. T.Schermer@hag.umcn.nl
authors.forename: Tjard
authors.initials: T
authors.lastname: Schermer
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Heijdra
authors.forename: Sabina
authors.initials: S
authors.lastname: Zadel
authors.forename: Lisette
authors.initials: L
authors.lastname: van den Bemt
authors.forename: Leandra
authors.initials: L
authors.lastname: Boonman-de Winter
authors.forename: Richard
authors.initials: R
authors.lastname: Dekhuijzen
authors.forename: Ivo
authors.initials: I
authors.lastname: Smeele
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000420:Albuterol; D001993:Bronchodilator Agents; D003430:Cross-Sectional Studies; D005194:Family Practice; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000503:physiopathology*; D012720:Severity of Illness Index; D012907:Smoking / Q000503:physiopathology; D013147:Spirometry; D014797:Vital Capacity / Q000187:drug effects
chemical_list: D001993:Bronchodilator Agents; D000420:Albuterol